Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs
11 Junho 2019 - 5:10PM
Business Wire
Company to Host Conference Call and Live
Webcast on Tuesday, June 25, 2019 at 1:30 p.m. Pacific Time/4:30
p.m. Eastern Time
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
therapies, today announced that the Company will host a conference
call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m.
Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on
its clinical and preclinical programs.
Investors interested in listening to the conference call may do
so by dialing (866) 211-3164 in the U.S. or (647) 689-6573
internationally, using Conference ID: 7163128.
To access the live webcast and accompanying slide presentation,
please visit the “Investors” section of the Arcus website at
www.arcusbio.com. Following the live webcast, a replay will be
available on the Company’s website for approximately 30 days.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer therapies. Arcus has
several programs targeting important oncology/immuno-oncology
pathways, including a dual adenosine receptor antagonist, AB928,
which is in a Phase 1/1b program to evaluate AB928 in combination
with other agents in multiple tumor types, and an anti-PD-1
antibody, AB122, which is being evaluated in a Phase 1 trial and is
being tested in combination with Arcus’s other product candidates.
Arcus’s other programs include AB154, an anti-TIGIT antibody, which
is being evaluated in a Phase 1 trial as monotherapy and in
combination with AB122, and AB680, a small-molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has
extensive in-house expertise in medicinal chemistry, oncology,
immunology, biochemistry, pharmacology and structural biology.
Utilizing these unique capabilities, Arcus has developed a robust
and active early stage discovery effort focused on small-molecule
pipeline expansion. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190611005782/en/
Katherine Bock(510) 694-6231kbock@arcusbio.com
Nicole Arndt(510) 284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024